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iPrenatal Megacystis – Is prediction of outcome and renal function 
possible? 
 
 
  
2 
Introduction 
Foetal megacystis is a rare but potentially curable foetal disease with a 9 to 1 male 
predominance. The cause is either morphological or functional obstruction of the foetal 
urethra. The main problem after prenatal detection of foetal megavesica is parental 
counselling as to the prognosis for the individual case.  Up to now the decision for 
prenatal intervention is based mainly on urine analysis first reported by Glick and 
refined by Johnson 1995 using sequential vesicocentesis [1],[2]. Recent metaanalysis 
revealed that antenatal testing of renal function is of variable accuracy [3]. Case reports 
and small series have demonstrated that renal function cannot be predicted by fixed 
cut-offs of urine analysis alone. [4] [5], [6] [7]. Recent reports emphasise that besides 
urine electrolytes, osmolarity and beta-2-microglobuline renal sonomorphology and 
amount of amniotic fluid may be  predictors for postnatal renal function [8], [9], [10]. 
Management options include vesicocentesis, vesicoamniotic shunting and operative 
foetal cystoscopy with laser ablation of urethral valves [11], [12], [3], [13]. Long-term 
outcome of foetuses treated with vesicoamniotic shunting for lower urinary tract 
obstruction is scarce [14], [15]. Systematic review of the effectiveness of antenatal 
intervention give limited evidence that intervention seems to improve perinatal 
outcome particularly in cases with predicted poor outcome [16]. A recent randomised 
controlled trial presented higher survival rates after vesicamniotic shunting, but due to 
poor recruitment the effect could not be proven and subgroup analysis was impossible 
[17].  
In a recent paper, criteria for fetal interventions were presented on the basis of fetal 
urine biochemistry [18] 
The aim of our study is to document the clinical experience of antenatal management 
of foetal megavesica and describe postnatal outcome in relation to antenatal test 
results in a series of consecutive patients cared for in one institution. This is a basis for 
parental counselling. 
  
3 
Methods 
In a retrospective study at the Department of Obstetrics, University Hospital Zurich and 
at the University Children’s Hospital Zurich we describe prenatal management and the 
long-term outcome of foetal megavesica. From October 1995 till December 2008 53 
cases of foetal megacystis were diagnosed at our tertiary referral centre. During this 
time period a total of 26'675 women gave birth at our institution which gives a 
prevalence for foetal megavesica of 0.2%. Recent data from a population-based 
epidemiological study gives prevalence rates of 3.34 per 10 000 births [19]. Therefore 
we are dealing with a highly selected population in a tertiary referral centre.  
Gestational age at referral ranged from 12 to 34 weeks of gestation. The bladder size 
was measured by ultrasound in three planes from a transversal and longitudinal section 
of the foetus. The diagnosis of foetal megacystis in the first half of pregnancy was 
made, if the mean bladder diameter was more than 20mm. In this patient population 
spontaneous resolution is reported to be exceptional  [20], [11]. During the second half 
of pregnancy in addition to increased bladder size, oligohydramnios according to the 
largest pocket method and dilatation of foetal renal pelvis must be present. The 
sonographic exams were performed using standard Ultrasound equipment (Acuson 
XP, Siemens Elegra and Voluson 730 Expert) by an experienced sonographer (J.W.). 
If the inclusion criterion for megacystis was met, the patients were counselled as to the 
uncertain prognosis and diagnostic procedures were offered in order to clarify the 
situation. As a first step we offered vesicocentesis to evaluate urine electrolytes 
(sodium, chloride and calcium), urine osmolarity and urine β2-microglobulin as well as 
a cytogenetic examination of the foetus.  
On the basis of the actual knowledge and published guidelines [1], [2] patients were 
counselled and decided either to proceed with pregnancy with repeated punctures or 
to opt for termination of pregnancy. 
With the informed consent from the parents we collected data on the clinical course of 
these children and obtained data from a follow-up period of 2 to 12 years from the 
documents of the paediatrician. We documented the diagnostic and therapeutic 
procedures and the actual clinical situation with special interest in the creatinine levels. 
Kidney function was classified as normal or impaired according to serum creatinine 
values using sex and age-specific reference ranges [21].   
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Clinical follow-up and assessment of outcome was performed for all 15 patients who 
continued pregnancy and survived neonatal period.  
In order to evaluate the prognostic values of urine analysis, we compared the values 
from the 10 surviving foetuses with prenatal vesicocentesis (one surviving female with 
trisomy 21 excluded) with 11 foetuses who died either pre- or postnatally without 
concomitant malformations. In cases of recurrent foetal vesicocentesis, the last 
available foetal urine sample was used for prognostic assessment.  
Statistical analysis included logistic regression analysis and ROC curves calculation 
for the gestational age dependent variables β2-microglobulin, osmolarity and chloride 
in order to draw the discrimination line between survivors and non-survivors (cases 
after termination excluded). In addition the amount of amniotic fluid according to the 
deepest pocket method was correlated with postpartum renal function, applying 
Fisher’s exact test to assess  statistical significance. 
  
5 
Results 
The description of the study population is presented in Fig 1 
From the total of 53 cases of megavesica 47 cases (88,7%) were diagnosed before 
and 6 cases (11,3%) after the 24th week of gestation.   
In 43 of the 53 cases (81,1 %) vesicocentesis was performed. In three cases (5,6%) at 
13, 14 and 16 weeks of gestation, megavesica resolved spontaneously before the 
procedure was performed. In 7 cases (13,2%) no vesicocentesis was performed either 
because of contraindication (maternal HIV-infection) or refusal of the parents.  
The diagnostic examination included a cytogenetic evaluation in 47 out of 53 cases 
either from amniotic fluid or the evaluation of foetal urine. In 41 cases we found a 
normal karyotype, whereas 6 foetuses presented aneuploidies (three cases 47,XY + 
13, two cases 47,XY + 18 and one case  47,XX + 21).  
Termination of pregnancy was performed in 23 cases. 5 cases had an abnormal 
karyotype (trisomies 13 and 18). Pathological values of vesicocentesis, oligo- or 
ahydramnion and the wish of the parents were the reason for the remaining 18 cases. 
There were 3 (5.7 %) intrauterine foetal deaths and 12 children (22.6 %) died 
postnatally. (Figure 1)  
Postnatal renal function of the 15 survivors was classified according to published age- 
and sex-related creatinine values into normal and impaired renal function (RF) [21]. 
Thereafter the children were grouped according to the necessary neonatal and 
paediatric treatment (Tab 1). 8 children survived with normal renal function whereas 7 
presented with impaired renal function after operative interventions. 
The prognostic value of amniotic fluid volume for the assessment of postnatal renal 
function is presented in the following Tab. 2 and summarized graphically in Fig. 2 
Applying Fisher’s exact test to data presented in Tab. 2 show that there is a significant 
association between normal amniotic fluid and normal renal function post partum and 
abnormal amniotic fluid with impaired renal function or perinatal death (PD)  (p = 
0.0027).  
 
Logistic regression of urine β2-microglobulin (Fig. 3a), osmolarity (Fig.4a) and chloride 
(Fig. 5a) in relation to gestational age for the 10 survivors (foetus with trisomy 21 
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excluded) and 11 perinatal deaths (termination of pregnancy excluded) as well as 
corresponding ROC-curves (Fig. 3b, 4b, and 5b) are presented in the following graphs. 
For β2-microglobulin Fig. 3 shows complete discrimination between survivors and non-
survivors by the calculated gestational age dependant regression line. 
For osmolarity and chloride the presented regression line show clinically helpful 
discrimination between the two groups and ROC-curves show area under the curve 
(AUC) of 0.81 and 0.76, respectively.  
In the group of 11 surviving children with vesicocentesis, including  the child with 
trisomy 21, prenatal urine analysis including β2-microglobulin, osmolarity and chloride 
does not discriminate between postnatal normal and impaired renal function. (Fig 6 a-
c) 
 
 
 
 
  
 
 
 
Discussion:  
Foetal megavesica is a rare condition with a prevalence of 0.06 % in screening 
population [22], whereas in our tertiary center the prevalence was 0.2% which is as 
high as previously described for referral centers [23]. The condition is potentially 
curable but published mortality rates in tertiary centers is high, with 15 out of 16 
foetuses dying (93.8%) [23]. Actual data from the same institution show only 6 
survivors out of 72 fetuses (8.3%) [18]. In a recent randomised controlled trial (PLUTO 
trial) only 31 out of 99 pregnancies were continued. Only ten children survived the 2-
year period which gives a total mortality rate of 89.9% and a 64.5% mortality in ongoing 
pregnancies [17]. In our series 30 of 53 pregnancies continued after prenatal 
diagnosis. In 15 cases perinatal deaths occurred which gives a mortality of 50% for 
ongoing pregnancies and 71.7 % total mortality. We observed only 3 of 53 (5.7%) 
foetuses showed spontaneous remission whereas in another  screening population 
7 
with less strict inclusion criteria, the spontaneous remission rate was 8 out of 15 
(53.3%) [22]. These data show that besides our strict inclusion criteria for the diagnosis 
of fetal megavesica, the prognostic assessment in our patients is rather better than in 
the PLUTO trial and other published series. 
8 of our 15 survivors had a normal renal function at a maximum of 12 years and a 
minimum of 2 years of age.  The PLUTO trial reported only 2 out of 10 survivors with 
normal renal function whereas 7 children had moderate, and 1 end-stage renal function 
impairment.   
Our study shows that in 6 out of 47 (12,8%) foetuses  megavesica was associated with 
an abnormal karyotype. The prevalence and the spectrum of chromosomal anomalies 
is comparable to previously published data. In the largest series of foetuses with 
megavesica > 15mm during the first trimester, 4 out of 35 (11.4%) have a chromosomal 
anomaly [20]. Therefore, foetal karyotyping is a keystone in the prenatal evaluation of 
foetal megavesica. 
Prenatal counselling as to the prognosis and the postnatal outcome is difficult and 
currently not based on profound scientific evidence. Our data confirm that renal 
function is associated with the amount of amniotic fluid. Reduced amniotic fluid has a 
significantly higher risk for impaired postnatal renal function and perinatal death 
compared to normal amniotic fluid. Another prognostic factor seems the 
sonomorphologic appearance of the foetal kidneys, which we could not evaluate in our 
retrospective study [8],[24]. However, using sonomorphology, one has to take into 
account the gestational age dependent changes of renal echogenicity.  
The cornerstone for the estimation of foetal renal function is the assessment of urine 
biochemistry, originally described by Glick [3]. Various studies cast doubt on the fixed 
cut-off values proposed by Glick and instead described gestational age dependent 
reference curves for urine markers [25], [4], [18].  
Our data show a gestational age-dependent discrimination line of foetal urine β2-
microglobulin, which allows discrimination between survivors and perinatal deaths from 
the beginning of second trimester onwards. For foetal urine osmolarity and foetal urine 
chloride we presented a discrimination line between those two groups which is clinically 
helpful as shown in the ROC-curves. 
Unfortunately, our data were unable to demonstrate (Fig.6) that foetal urine osmolarity 
and foetal urine β2-microglobulin can  discriminate between postnatal normal or 
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impaired renal function. The graph suggests that low β2-microglobuline values during 
the first half of gestation seem to be associated with normal postnatal renal function. 
Only larger series can definitively clarify this issue. 
According to our data and supported by previous work, a fixed cut-off level of foetal 
urine markers is not helpful in the counselling of parents with foetal megavesica. 
Furthermore, such fixed cut-offs are not helpful in decision-making for foetal invasive 
procedures. Therefore systematic reviews based on these parameters are far from 
being evidence based [16].    
Prediction of outcome and renal function in foetuses with megacystis is still 
challenging. Implementing gestational age-dependent cut-off lines for foetal urine 
markers as described, may be helpful in patient counselling. In our set-up 23 out of 53 
parents (43.4%) opted for termination of pregnancy (TOP), whereas is other series in 
tertiary centers the rate for TOP was 53 out of 72 (73.6%) fetuses.  
In the literature, the determination of fetal urinary peptides using capillary 
electrophoresis coupled with mass spectrometry seems a promising approach to 
predict foetal prognosis [26]. The measurement of urinary gamma-glutamyl-
transpeptidase (GGTP) can predict urodigestive fistulae [18].  
In conclusion, our study shows that fetal urine analysis can discriminate between 
survivors and non-survivors with high reliability, when using gestational-age dependent 
regression lines for β2-microglobuline, osmolarity and chloride. Therefore, these data 
are important for parent counselling and as selection criteria for fetal interventions. In 
order to prove this concept of parent counselling the presented regression lines need 
to be assessed in prospective studies. 
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